MeSH

A benzophenone and nitrophenol compound that acts as an inhibitor of CATECHOL O-METHYLTRANSFERASE, an enzyme involved in the metabolism of DOPAMINE and LEVODOPA. It is used in the treatment of PARKINSON DISEASE in patients for whom levodopa is ineffective or contraindicated.

Year introduced: 2019 (1990)

Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists.

Year introduced: 1976

Compounds and drugs that inhibit or block the activity of CATECHOL O-METHYLTRANSFERASE enzymes. Drugs in this class are used in management of central nervous system disorders such as PARKINSON DISEASE.

Year introduced: 2015

Organic compounds containing a carbonyl group =C=O bonded to two hydrocarbon groups.

Organic compounds derived from BENZENE.

Year introduced: 1968

Derivatives of benzophenone (with the structural formula phenyl-(C=O)-phenyl).

Year introduced: 1968

Organic compounds that primarily contain carbon and hydrogen atoms with the carbon atoms forming a linear or circular structure.

Organic compounds containing carbon and hydrogen in the form of an unsaturated, usually hexagonal ring structure. The compounds can be single ring, or double, triple, or multiple fused rings.

Year introduced: 1998

Organic compounds composed exclusively of carbon and hydrogen forming a closed ring that may be either alicyclic or aromatic.

Year introduced: 1998

Compounds having the nitro group, -NO2, attached to carbon. When attached to nitrogen they are nitramines and attached to oxygen they are NITRATES.

Year introduced: 1974(1971)

PHENOLS carrying nitro group substituents.

A broad class of substances containing carbon and its derivatives. Many of these chemicals will frequently contain hydrogen with or without oxygen, nitrogen, sulfur, phosphorus, and other elements. They exist in either carbon chain or carbon ring form.

Year introduced: 1998

Benzene derivatives that include one or more hydroxyl groups attached to the ring structure.

Drugs used in the treatment of movement disorders. Most of these act centrally on dopaminergic or cholinergic systems. Among the most important clinically are those used for the treatment of Parkinson disease (ANTIPARKINSON AGENTS) and those for the tardive dyskinesias.

Year introduced: 1995

Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.

Year introduced: 1975(1964)

A class of drugs producing both physiological and psychological effects through a variety of mechanisms. They can be divided into specific agents, e.g., affecting an identifiable molecular mechanism unique to target cells bearing receptors for that agent, and nonspecific agents, those producing effects on different target cells and acting by diverse molecular mechanisms. Those with nonspecific mechanisms are generally further classed according to whether they produce behavioral depression or stimulation. Those with specific mechanisms are classed by locus of action or specific therapeutic use. (From Gilman AG, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p252)

Year introduced: 1979

A group of pharmacologic activities, effects on living systems and the environment, and modes of employment of drugs and chemicals. They are broken into actions, which describe their effects, and uses, which describe how they are employed.

Year introduced: 1999

A broad category of chemical actions and uses that result in the prevention, treatment, cure or diagnosis of disease. Included here are drugs and chemicals that act by altering normal body functions, such as the REPRODUCTIVE CONTROL AGENTS and ANESTHETICS. Effects of chemicals on the environment are also included.

Year introduced: 2004(1999)

Pharmacological activities at the molecular level of DRUGS and other exogenous compounds that are used to treat DISEASES and affect normal BIOCHEMISTRY.

Year introduced: 2008(2004)

Uses of chemicals which affect the course of conditions, diseases, syndromes or pathology to benefit the health of an individual.

Year introduced: 2004